|
|
Comparison of efficacy and prognosis between LVIS stent and EP stent assisted embolization for communicating wide-neck aneurysms |
WU Zhonghua1 LONG Liansheng2 FANG Wenjie2 WANG Wei2 SHI Shunxiao2 LI Xialiang2 SHENG Wenguo2 |
1.Graduate School, Zhejiang Chinese Medicine University, Zhejiang Province, Huzhou 310053, China; 2.Department of Neurosurgery, South Taihu Hospital Affiliated to Huzhou College, Zhejiang Province, Huzhou 313000, China |
|
|
Abstract Objective To compare the efficacy and prognosis of stent and EP stent assisted embolization for communicating wide-neck aneurysms. Methods The clinical data of 84 patients with posterior communicating wide-neck aneurysms treated in South Taihu Hospital Affiliated to Huzhou College from September 2019 to December 2022 were collected for prospective analysis. According to the random number table method, they were divided into two LVIS group (LVIS stent) and EP group (EP stent), with 42 cases in each group. The clinical efficacy, biomarker levels, incidence of complications, and prognosis between the two groups were compared. Results After six months of follow-up, the clinical effect of EP group was better than that of LVIS group (P<0.05). There was no significant difference in recurrence rate between the two groups (P>0.05). 24 h after operation, the levels of serum vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9(MMP-9) in two groups were lower than those before operation, with statistical significance (P<0.05). There were no significant differences in serum VEGF and MMP-9 levels between the two groups 24 h after operation (P>0.05). There was no significant difference in the incidence of complications and clinical prognosis between the two groups (P>0.05). Conclusion LVIS stents and EP stents have similar therapeutic and prognostic effects in assisting embolization of wide-neck aneurysms, with high safety, and stents can be selected according to specific needs in clinical practice.
|
|
|
|
|
[1] 王红平,徐翔,王大永,等.Neuroform Atlas支架辅助弹簧圈治疗破裂前交通动脉宽颈动脉瘤的初步应用[J].中华神经外科杂志,2021,37(8):59-64. [2] 陈柏宇,曹毅,鲍娟,等.支架辅助弹簧圈栓塞治疗前交通动脉宽颈动脉瘤[J].中国卒中杂志,2021,16(6):544- 550. [3] 易田康.Lvis支架与Enterprise支架辅助弹簧圈栓塞治疗颅内宽颈动脉瘤的效果对比[J].临床医学工程, 2021, 28(6):739-740. [4] 于嘉,邓剑平,张登文,等.LVIS支架辅助栓塞颅内未破裂动脉瘤的临床疗效[J].中华神经外科杂志, 2017, 33(8):775-779. [5] 刘钊,陈鹏,车彦军,等.对比性分析LVIS支架和Enterprise支架辅助弹簧圈栓塞颅内破裂宽颈动脉瘤的安全性和有效性[J].临床神经外科杂志,2022,19(6):693- 698. [6] 卢万俊,韩长鸣,高峰,等.支架辅助栓塞治疗小型颅内宽颈动脉瘤的安全性及有效性[J].实用临床医药杂志,2021,25(22):82-86. [7] 董圆振,夏昆,吴云虎.颅内动脉瘤患者血NLR变化特点及其与Hunt-Hess评分的相关性分析[J].医学信息,2022,35(8):101-104. [8] 凌国源,莫立根,冯大勤,等.Lvis支架与Enterprise支架辅助栓塞颅内宽颈动脉瘤的比较[J].中国微创外科杂志,2020,20(9):769-774. [9] 施磊,陈赟东,冷硕,等.支架辅助弹簧圈栓塞颅内破裂动脉瘤疗效及安全性分析[J].临床神经外科杂志,2022, 19(1):22-28. [10] 马亚伟,胡振坤,徐睿,等.支架辅助弹簧圈栓塞治疗大脑前动脉A1段起始处破裂微小动脉瘤[J].中国临床神经外科杂志,2021,26(3):145-148. [11] 易田康.Lvis支架与Enterprise支架辅助弹簧圈栓塞治疗颅内宽颈动脉瘤的效果对比[J].临床医学工程,2021, 28(6):739-740. [12] 田涛,彭汤明,万伟锋,等.LVIS支架联合弹簧圈栓塞急性期颅内破裂宽颈动脉瘤的临床疗效[J].中国脑血管病杂志,2018,15(5):248-253. [13] 冯冠军,黄啸元,王东海,等.LVIS支架辅助弹簧圈栓塞治疗急性期破裂出血后交通动脉瘤的疗效观察[J].中华实用诊断与治疗杂志,2022,36(9):921-924. [14] 刘建武,祝斐,陈志华,等.LVIS支架辅助栓塞宽颈脉络膜前动脉动脉瘤疗效分析[J].海军军医大学学报,2022, 43(2):224-228. [15] Fan W,Gu J,Shen J,et al. Effect analysis of enterprise and LVIS stents in the treatment of internal carotid artery ophthalmic segment aneurysms [J]. Minerva Med,2023,114(1):135-136. [16] 冯冠军,黄啸元,王东海,等.LVIS支架辅助弹簧圈栓塞治疗急性期破裂出血后交通动脉瘤的疗效观察[J].中华实用诊断与治疗杂志,2022,36(9):921-924. [17] 姚磊,吴琪,文立利,等.Enterprise支架重建技术治疗椎动脉夹层动脉瘤的效果分析[J].中国脑血管病杂志,2021,18(1):18-24. [18] 张坤,王子亮,李天晓,等.Enterprise支架在颅内缺血性疾病治疗中的应用与前景[J].介入放射学杂志,2021, 30(5):533-536. [19] 邵东传,吴钧,高云,等.LVIS支架辅助弹簧圈栓塞治疗颈内动脉床突上段夹层动脉瘤[J].中国临床神经外科杂志,2022(8):629-632. [20] Kim YN,Choi JW,Lim YC,et al. Usefulness of Silent MRA for Evaluation of Aneurysm after Stent-Assisted Coil Embolization [J]. Korean J Radiol,2022,23(2):246-255. [21] Saied A,Elsaid N,Joshi K,et al. Factors Affecting the Degree of Angular Remodeling in Stent-Assisted Coiling of Bifurcation Aneurysms [J]. Interv Neurol,2020,8(2/6):220- 230. [22] 孙运帅,王诗良,李一星,等.LVIS支架释放前后颅内动脉瘤瘤腔内压力变化的研究[J].临床神经外科杂志,2021,18(1):88-91. [23] 朱宗锦,刘保华,袁璞,等.LVIS支架辅助弹簧圈栓塞治疗颅内破裂宽颈动脉瘤的疗效[J].安徽医学,2022,43(11):1272-1275. [24] 潘晓蓉,鲁亦捷,姜坤.化瘀消斑汤治疗颈动脉粥样硬化性脑梗死的临床研究及对hs-CRP、VEGF、MMP-9因子的影响[J].贵州医药,2018,42(9):1054-1056. [25] 潘新元,黄晖,韦奎丞,等.早期生长反应因子1调控增殖期婴幼儿血管瘤血管内皮生长因子和基质金属蛋白酶-9的表达[J].中国当代医药,2022,29(33):5-9,197. [26] 荣钰,董莉.血清MMP-9,TIMP-1及VEGF水平检测对冠状动脉支架内再狭窄诊断的研究进展[J].现代检验医学杂志,2021,36(1):161-164. [27] 何敬,马楠,霍红,等.血清血管内皮生长因子、同型半胱氨酸与视网膜静脉阻塞黄斑水肿程度的相关性分析[J].中国医药导报,2023,20(1):107-110. |
|
|
|